Benchmark Reiterates Buy Rating on MiniMed Group (MMED) Following Better-Than-Expected Q4

June 4, 2026 9:26 AM

Benchmark analyst Bruce Jackson reiterated a Buy rating and $20.00 price target on MiniMed Group (NASDAQ: MMED).The analyst commented, "MiniMed ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found